OVA1 Research Results

OVA1 test by Vermillion is a blood test that evaluates whether an ovarian mass is cancerous prior to surgery. OVA1 is FDA approved for that purpose. CA-125 is one of the five biomarkers used in the OVA1 test. The other markers are Beta-2 microglobulin, apoliprprotein A-1, prealbumin, and transferrin. The test results are evaluated using a proprietary algorithm to produce a result.  The resulting number is between 0-10.

Recently a study of OVA1 was published in the Journal Gynecologic Oncology .

Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay

The study included 494 patients from multiple centers. Blood samples (taken prior to surgery) and physicians risk assessments were correlated with surgical pathology reports.
Ova1 correctly predicted ovarian cancer 91% of the cases of early stage cancer vs 65.7% using CA-125 alone. The OVA1 test was also better at  predicting the absence of disease with a negative predicitive vale of 98.1%.

The study concluded that the OVA1 - 5 marker test "demonstrated higher sensitivity and negative predictive value for ovarian malignancy compared to clinical impression and CA125-II in an intended-use population of non-gynecologic oncology practices."

It is a very interesting study.

Dee
Every Day is a Blessing!